– USA, MA – Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the additions of Kate Haviland and Scott Robertson to its Board of Directors.
Scott Robertson will join the audit committee as chair.
About Kate Haviland
Kate currently serves as the president and CEO of Blueprint Medicines, having held the previous roles of COO and CBO. Before joining Blueprint Medicines, Kate held leadership roles focused on building emerging, high-growth companies and advancing the development of innovative therapies in oncology and rare diseases as VP of rare diseases and oncology program leadership at Idera Pharmaceuticals, head of commercial development at Sarepta Therapeutics, executive director of commercial development at PTC Therapeutics, and roles in both corporate development and project management at Genzyme. She also serves as chair of the board of directors at Fulcrum Therapeutics.
Kate holds an MBA from Harvard Business School and received her B.A. from Wesleyan University with a double major in biochemistry/molecular biology and economics.
About Scott Robertson
Scott served as CBFO of DICE Therapeutics before its acquisition by Eli Lilly and Company for approximately $2.4 billion. Before DICE, Scott served as business development director for DuPont Pioneer, with responsibility for mergers & acquisitions and strategic partnerships. He also held the position of portfolio manager with DuPont Ventures, where he focused on strategic investment opportunities in crop genetics and precision agriculture. Before joining DuPont, Scott was an investment professional at MPM Capital, a life sciences-dedicated venture capital fund, and before that, he was a member of the healthcare investment banking teams at Merrill Lynch & Co. and Thomas Weisel Partners.
Scott holds an MBA from the Haas School of Business at the University of California, Berkeley, and received his B.S. in business administration from the University of Southern California.
About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to combine the precision of well-validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara’s lead product candidate, BCA101, is a first-in-class EGFR/TGF-β-trap bifunctional antibody currently being evaluated in a Phase 1/1b study.
For more information: https://www.bicara.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
